** Specialty pharma firm 60 Degrees Pharmaceuticals' SXTP.O shares rise 5.6% to 63 cents in afternoon trade
** Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.
** Arakoda is an antimalarial drug for the prophylaxis of malaria in patients aged 18 years and older in the U.S.
** The drug is sold under the brand name Kodatef in Australia
** The drug is not approved for use in the U.S.
** SXTP plans to import a five-month supply of Kodatef while increasing manufacturing of Arakoda over long term
** Co says the two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features
** In the last 12 months, stock has fallen 80.2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。